



Gamida Cell to Present Corporate Highlights at the H.C. Wainwright 25th Annual Global Investment Conference

August 31, 2023

BOSTON--(BUSINESS WIRE)--Aug. 31, 2023-- [Gamida Cell Ltd.](#) (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that its management team will present corporate highlights at the upcoming [H.C. Wainwright 25th Annual Global Investment Conference](#) in New York, NY.

Presentation Details

Format: Fireside chat

Date and time: Available on-demand Monday, September 11, 2023, at 7 a.m. ET for conference registrants

The Gamida Cell management team will be available for one-on-one meetings during the conference. Interested investors should contact their H.C. Wainwright representative.

About Gamida Cell

Gamida Cell is a cell therapy pioneer working to turn cells into powerful therapeutics. The company's proprietary nicotinamide (NAM) technology leverages the properties of NAM to enhance and expand cells, creating allogeneic cell therapy products and candidates that are potentially curative for patients with hematologic malignancies. These include Omisirge[®] (omidubicel-ONLY), an FDA-approved nicotinamide modified allogeneic hematopoietic progenitor cell therapy, and GDA-201, an intrinsic NK cell therapy candidate being investigated for the treatment of hematologic malignancies. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on [LinkedIn](#), [X](#), [Facebook](#) or [Instagram](#).

Omisirge[®] is a registered trademark of Gamida Cell Inc. © 2023 Gamida Cell Inc. All Rights Reserved.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the potentially life-saving or curative therapeutic and commercial potential of Omisirge[®] (omidubicel-ONLY), and the Company's cell therapy candidate, GDA-201. Any statement describing Gamida Cell's goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions including those related to clinical, scientific, regulatory and technical developments and those inherent in the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cell's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 14, 2023, and other filings that Gamida Cell makes with the SEC from time to time (which are available at www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and Gamida Cell's actual results could differ materially and adversely from those anticipated or implied thereby. Although Gamida Cell's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Gamida Cell. As a result, you are cautioned not to rely on these forward-looking statements.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230830831135/en/): <https://www.businesswire.com/news/home/20230830831135/en/>

Investor Contact:

Chuck Padala
LifeSci Advisors
Chuck@lifesciadvisors.com
1-646-627-8390

Media Contact:

Dan Boyle
Orangefiery
media@orangefiery.com
1-818-209-1692

Source: Gamida Cell Ltd.